Peer-influenced content. Sources you trust. No registration required. This is HCN.
British Medical Journal (The BMJ)
Many studies have a high risk of bias and significant heterogeneity, implying that results should be interpreted with caution. Nonetheless, most estimates of symptom change for general mental health, anxiety symptoms, and depression symptoms were close to zero and not statistically significant, and significant changes were of minimal to minor magnitudes. In all domains, women or female participants experienced minor negative changes.
Psychiatry March 14th 2023
Patients with long COVID may present in primary care with symptoms of palpitations from tachycardia triggered by standing or even limited exertion. Palpitations can be accompanied by other autonomic nervous symptom-associated symptoms such as dizziness, breathlessness, chest pain, sweating, bloating, and fatigue, and patients can find these symptoms debilitating.
Cardiology March 8th 2023
Infectious Disease Special Edition (IDSE)
Reports on the Vaccine Safety Datalink flagged the need to investigate a potential increased risk those 65 years of age and older, for ischemic stroke in the first 21 days after receiving the bivalent Pfizer-BioNTech booster. FDA has parallel monitoring systems to confirm or fail to validate a safety signal. In this case, those other systems did not confirm the Vaccine Safety Datalink flag.
Allergy & Immunology January 24th 2023
Blood
In this extensive survey, patients with hematologic malignancies who have breakthrough COVID-19 have approximately 9% reduced mortality rate than they did before vaccination. Patients who received monoclonal antibodies, either alone or in conjunction with antivirals, had superior clinical results.
Hematology January 9th 2023
We can better understand outcomes in patients with a variety of ages, ethnicities, comorbidities, and exposures by using observational data. It can be challenging or even impossible to disentangle the diverse effects of dynamic elements like vaccination rates, patient behaviors, and COVID-19 pathogenicity. Randomized controlled trials involving blood cancer patients are required to fully assess the impact of COVID-19 therapies. The impact of both bivalent vaccines and prophylactic monoclonal antibodies, as well as ways to assure equitable distribution of COVID-19 vaccines and therapies, will all be determined by future study. Some of those studies must involve people who have hematologic malignancies.
JAMA Network
In this cohort study of 12,046 patients with cancer and COVID-19, it was discovered that the use of immunotherapy (IO) and other systemic anticancer therapies in combination with baseline immunosuppression was linked to worse outcomes and a higher incidence of cytokine storm in SARS-CoV-2-infected cancer patients.
Oncology, Medical November 14th 2022